构成性NOS生产是由阿尔茨海默病病理学调节的,这取决于APOE基因型
Chiara Giuseppina Bonomi1, Alessandro Martorana1, Denise Fiorelli2
1UOSD Memory Clinic, Policlinico Tor Vergata, University of Rome "Tor Vergata", 00133 Rome, Italy.
International journal of molecular sciences
|April 13, 2024
概括
患有APOE ε3基因型的阿尔茨海默氏病患者的氧化合成酶 (NOS) 水平增加,这表明与APOE ε4载体相比,血管对粉样蛋白病理的反应不同.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 遗传学 遗传学 是一个
背景情况:
- 氧化合成酶 (NOS) 异型,包括内皮 (eNOS) 和神经 (nNOS),与阿尔茨海默病 (AD) 的血管功能障碍有关.
- APOE基因型影响AD病理和血管反应.
研究的目的:
- 研究阿尔茨海默病患者的粉样蛋白病理和氧化 (NO) 动态之间的关系.
- 为了比较脑脊液 (CSF) 的nNOS和eNOS与APOE基因型,AD生物标志物和血管因素相关的水平.
主要方法:
- 脑脊液 (CSF) 的eNOS和nNOS水平在8名健康对照 (HC) 和27名AD患者中进行测量.
- 患者根据APOE ε基因型 (ε3和 ε4) 分层.
- 研究了与CSFAD生物标志物,年龄,性别,认知衰退和血脑屏障透性的关联.
主要成果:
- 与HC和APOE ε4 AD患者相比,APOE ε3 AD患者的eNOS和nNOS水平都增加了.
- 在APOE ε3载体中,CSF eNOS与CSF Amyloid-β42相反相关.
- 在APOE ε4载体中,CSF nNOS与年龄和CSF p-tau负相关.
结论:
- APOE基因型调节了对AD病理的血管反应,影响了NOS异型水平.
- 在APOE ε3中增加的eNOS可能表明对抗Aβ诱导的血管收缩的补偿性血管扩张.
- 在APOE ε3中nNOS的激活可能反映了NO介导的可塑性策略.
更多相关视频
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.3K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.9K
相关概念视频
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
